Study M876
Study name | Paul ER 2022 |
Title | Peripheral and central kynurenine pathway abnormalities in major depression |
Overall design | In this study, a broad, multi-level assessment of abnormalities in the kynurenine pathway in the periphery as well as the CNS was conducted in a general, non-subtyped major depressive disorder (MDD). Kynurenine pathway-metabolites were measured levels in both plasma and cerebrospinal fluid (CSF) of depressed patients (MDD group, n = 63) and healthy controls (control group, n = 48). |
Study Type | Type1; |
Data available | Unavailable |
Organism | Human; |
Categories of depression | Depressive disorder; Depression; Depression; |
Criteria for depression | DSM-5 diagnosed MDD |
Sample size | 111 |
Tissue | Peripheral; Blood; Plasma; Central; Cerebrospinal fluid; Cerebrospinal fluid; |
Platform | MS-based; LC-MS: Waters Acquity UPLC I-Class FTN system (Waters, MA, USA) with Xevo TQ-XS triple-quadrupole mass spectrometer (Waters, Manchester, UK); |
PMID | |
DOI | |
Citation | Paul ER, Schwieler L, Erhardt S, et al. Peripheral and central kynurenine pathway abnormalities in major depression. Brain Behav Immun. 2022 Mar;101:136-145. |
Metabolite | Quinolinic acid; |
